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Abstract: Inhibiting ceramidase activity in cancer cells has been identified as a promising target for cancer therapy in recent studies.
Thus, we examined the possible role of ceranib-2, a novel ceramidase inhibitor, on growth and apoptotic mechanisms of the human
normal glia cell line (HNA), human glioma cell lines (T-98G and U-87MG), and a rat glioma cell line (C6). We also compared the results
with the effects of C2 ceramide and cisplatin. We determined the in vitro survival rate with MTT assay, apoptosis with flow cytometry,
gene expressions with qRT-PCR, and statistical significance by one-way analysis of variance together with Tukey’s test. Calculated from
MTT outcomes, the inhibitory ranking was as follows: T-98G > U-87MG > C6 > HNA. Ceranib-2 had the most growth-suppressive
activity on human T-98G cells with an IC50 of 7 µM for 24 h and 0.9 µM for 48 h. Only the 25 µM dose of ceranib-2 induced apoptosis
of human T-98G and U-87MG cells after 24 h of treatment; however, it increased apoptosis of C6 cells dose- and time-dependently.
Ceranib-2 increased the cytochrome c gene expression level during 24 h in T-98G cells. Ceranib-2 had cytotoxic and apoptotic effects
on glioma cells but the cytotoxic effect was weaker on normal glia cells. This cytotoxicity was stronger than that of C2 ceramide and
cisplatin.
Key words: Ceranib-2, C2 ceramide, cisplatin, apoptosis, glioma

1. Introduction
Grade IV astrocytoma or glioblastoma multiforme
(GBM) is an aggressive brain tumor. Although important
improvements furthered the conventional treatment
of GBM in recent decades, median survival of GBM
patients is still approximately 2 years (Jemal et al., 2009).
Sphingolipids are a major group of membrane lipids that
have important functions in a variety of cellular processes
including proliferation, growth, or cell death. The level of
such metabolites of sphingomyelin, a kind of sphingolipid
in cell membranes, is changed by a large number of factors
including chemotherapy, genotoxic stress, radiation,
growth factors, environmental stress, hormones, and
cytokines. Ceramide, sphingosine, sphingosine-1phosphate (S1P), and dihydroceramide are important
members of those bioactive sphingolipids. Most of these
metabolites contribute to signal transduction pathways
that regulate cell growth, differentiation, death, and
apoptosis (Viani et al., 2003; Oskouian et al., 2010).
Besides controlling sphingolipid signaling, ceramidase
enzyme lowers the level of ceramide and concomitantly
* Correspondence: gokhankus@anadolu.edu.tr

increases S1P and other bioactive metabolites (Realini et
al., 2016). Thus, ceramidase inhibitors that stop ceramide
catabolism or its conversion to other molecules have been
developed as cancer therapeutics. For example, levels
of ceramidase were found to be high in different cancer
types (Seelan et al., 2000; Strelow et al., 2000; Osawa et
al., 2005; Xu et al., 2006; Proksch et al., 2011). As a key
regulator, the equilibrium between S1P and ceramide
levels can regulate growth, differentiation, cell division,
and apoptosis in different cancer cell types (Oskouian
et al., 2010). Therefore, loss of balance between S1P and
ceramide might be very important in the determination
of cell fate. Based on this, we previously demonstrated
that prostate cancer cells were inclined to apoptosis
and cell death occurred when they were treated with a
ceramidase inhibitor, namely ceranib-2 (Kus et al., 2015).
For these reasons, we aimed to examine the possible role
of ceranib-2 on growth and apoptosis of a normal glia cell
line and three glioma cell lines, and also to compare the
outcomes with the effects of C2 ceramide and cisplatin, a
conventional anticancer drug.
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2. Materials and methods
2.1. Cell culture
Human glioma cell lines (T-98G, CRL-1690, up to 5
passages; U-87MG, HTB-14, up to 5 passages) and a rat
glioma cell line (C6, CCL-107, up to 5 passages) were
bought from the American Type Culture Collection.
Normal human astrocytes (NHAs, CC-2565, up to 3
passages) were purchased from Lonza. The cells were
grown in a complete medium recommended by the
supplier in a humidified incubator containing 5% CO2 at
37 °C. Ceranib-2, C2 ceramide (Cayman), and cisplatin
(Sigma) were dissolved in dimethyl sulphoxide (DMSO,
Sigma) and diluted in Dulbecco’s modified Eagle’s medium
(DMEM). The final concentrations of each drug ranged
from 0.1 to 50 µM. C2 ceramide and cisplatin were used
as positive controls.
2.2. Experimental groups
Control: Had only complete medium containing DMEM
supplemented with 10% fetal calf serum (Sigma) and 1%
penicillin-streptomycin solution (Sigma).
DMSO group: Final 0.1% DMSO (solvent) in complete
medium.
Cisplatin group: Treated with 0.1, 1, 5, 10, 25, and 50
µM cisplatin for 24 or 48 h.
C2 ceramide group: C2 ceramide at the doses of 0.1, 1,
5, 10, 25, and 50 µM applied for 24 or 48 h.
Ceranib-2 group: Treated with 0.1, 1, 5, 10, 25, and 50
µM ceranib-2 for 24 or 48 h.
2.3. MTT assay
Cytotoxic effects of the drugs were evaluated by using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide thiazolyl blue (MTT) colorimetric method
(Mosmann, 1983; Oztopçu et al., 2004). Briefly, cells
were inoculated into 96-well plates with 1 × 104 cells
per well and exposed continuously to the above range of
concentrations of the drugs for 24 and 48 h. Each well
was then treated with 1:10 MTT solution (5 mg/mL) and
the culture plates were incubated further for at least 3 h.
The medium in each well was then changed with 100 µL
of DMSO and mixed thoroughly for 5–10 min at room
temperature. The quantity of purple formazan, which is
produced by metabolically active cells and represents the
number of viable cells, was measured by using a platereading spectrophotometer (BioTek).
2.4. Apoptosis assay
Various methods have been developed to differentiate
live cells from early and late apoptotic cells and necrotic
cells. By using an apoptosis assay kit (Invitrogen), the
cells (T-98G, U-87MG, and C6) were first double-stained
with annexin V/FITC plus propidium iodide (PI) and
then the percentage of dead cells was determined with a
flow cytometer. Flow cytometric analysis was done with a
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FACSCalibur equipped with CellQuest Pro software (Park
et al., 2015).
2.5. Quantitative real-time polymerase chain reaction (qRT PCR) assay
After collecting the cells, the High Pure RNA Isolation
Kit (Roche Diagnostics) was used for total RNA
isolation. RNA was collected in elution buffer of the
same kit and stored at –80 °C until analysis. The optical
density at 260 nm (NanoDrop 1000, Thermo Scientific)
was measured for analyzing the concentration of total
RNA. cDNA was synthesized with 1000 ng of total
RNA from each sample by using a reverse transcriptase
cDNA synthesis kit (Roche Diagnostics). Using betaactin (forward: CAACCGTGAGAAGATGACTCAGA,
reverse:
CCCAGAGTCCATGACAATACCA)
as
a reference gene, the abundance of cytochrome c
(forward:
ACATCGTGCGAGCTAGGC,
reverse:
CTCGCAGTAGCCCGTGAG) mRNA was determined.
FAM-labeled primers/probes of the reference gene and the
target genes’ probes were amplified in 0.2-mL PCR tubes
containing 1 µL of primer, 10 µL of master mix, 4 µL of
RNAse-free water, and 5 µL of cDNA sample. Amplification
was determined using Dual Label TaqMan probes and the
measurements were done with a Roche Nano LightCycler.
Data were analyzed by relative quantification method with
2–ΔΔct calculations.
2.6. Statistical analysis
First one-way analysis of variance and then Tukey’s multiple
comparison tests were applied for statistical significance. P
< 0.05 was considered as significant. The MTT data and
apoptotic values were expressed as percentage of cells. At
least three independent experiments were carried out for
each group.
3. Results
3.1. MTT results
Cisplatin at concentrations of 0.1, 1, 5, and 10 µM did not
change the survival rates of T-98G cells after 24 or 48 h of
incubation, but with 25 and 50 µM doses, the rates of dead
T-98G cells versus control were about 28% and 29% after
24 h and 34% and 40% after 48 h, respectively (Table 1).
At lower concentrations, 0.1 and 1 µM cisplatin did not
change the survival rates of U-87MG after 24 or 48 h of
incubation. However, treatment of U-87MG cells with 5,
10, 25, and 50 µM cisplatin diminished the cell survival
rate versus the control at 22% (P < 0.05), 46%, 54%, and
60% (P < 0.001) after 24 h and at 30%, 54%, 58%, and 61%
(P < 0.001) after 48 h, respectively (Table 1). Similarly, 0.1,
1, and 5 µM cisplatin did not affect the survival rates of C6
cells after 24 or 48 h of incubation and 10, 25, and 50 µM
cisplatin killed C6 cells compared to the control by 8% (P
< 0.05), 30%, and 36% for 24 h and 17%, 65%, and 71%
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Table 1. Effects of cisplatin, C2 ceramide, and ceranib-2 doses and DMSO (vehicle) on T-98G, U-87MG, and C6 cell survival during 24
or 48 h of treatment. The table also shows 24 h of application of ceranib-2 on HNA cells. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
Applied

T-98G cells (%)

U-87MG cells (%)

C6 cells (%)

concentrations (µM)

24 h

24 h

24 h

48 h

48 h

HNA cells (%)
48 h

Control

100

100

100

100

100

100

DMSO (vehicle)

100

101

96

99

98

100

0.1 µM cisplatin

101

102

99

94

100

99

1 µM cisplatin

100

100

96

94

99

99

5 µM cisplatin

99

98

78 *

70 ***

99

98

10 µM cisplatin

94

80

54 ***

46 ***

92 *

83 *

25 µM cisplatin

72 **

66 **

46***

42 ***

70 ***

35 ***

50 µM cisplatin

71 **

60 **

40 ***

39 ***

64 ***

29 ***

Control

100

100

100

100

100

100

DMSO (vehicle)

100

95

97

98

98

95

0.1 µM C2 ceramide

101

102

96

98

101

85 ***

1 µM C2 ceramide

102

101

91

100

101

83 ***

5 µM C2 ceramide

102

100

86 ***

90 ***

99

83 ***

10 µM C2 ceramide

102

102

78 ***

69***

97

80 ***

25 µM C2 ceramide

79 ***

74 ***

64 ***

66 ***

89 ***

73 ***

50 µM C2 ceramide

42***

25 ***

14 ***

5 ***

53 ***

12 ***

24 h

Control

100

100

100

100

100

100

100

DMSO (vehicle)

97

95

97

98

97

95

99

0.1 µM ceranib-2

91

90

98

93

93

93

101

1 µM ceranib-2

62 ***

47 ***

96

90

85 ***

85 ***

99

5 µM ceranib-2

52 ***

40 ***

89 *

85 *

73 ***

70 ***

96

10 µM ceranib-2

47 ***

38 ***

41 ***

38***

70 ***

61 ***

80 **

25 µM ceranib-2

46 ***

36 ***

20 ***

17 ***

69 ***

60 ***

78 **

50 µM ceranib-2

39 ***

30 ***

18 ***

4 ***

60 ***

36 ***

72 ***

for 48 h, respectively (Table 1). At 0.1, 1, 5, and 10 µM, C2
ceramide did not show any significant activity on survival
of T-98G cells after 24 or 48 h of incubation, but 25 and 50
µM ceramide diminished the living cell numbers by 21%
and 58% (P < 0.001), respectively, for 24 h. After 48 h of
incubation, C2 ceramide at 25 and 50 µM diminished the
cell number of T-98G glioma by 26% and 75% (P < 0.001),
respectively (Table 1). C2 ceramide at the doses of 0.1 and
1 µM did not cause any significant change in the survival
rate of U-87MG cells after 24 and 48 h of incubation. After
applying C2 ceramide at 5, 10, 25, and 50 µM, the viability
of U-87MG was lessened by 14%, 22%, 36%, and 86% for
24 h and by 10%, 31%, 34%, and 95% for 48 h, respectively
(Table 1). Treatments with 0.1, 1, 5, and 10 µM C2 ceramide
did not change the survival of C6 cells; however, at 25 and
50 µM C2 ceramide decreased survival rates by 11% and
47% after 24 h, respectively. After 48 h of treatment, with

all doses of C2 ceramide the corresponding percentages
of dead C6 cells were 15%, 17%, 17%, 20%, 27%, and
88% (P < 0.001 for all), respectively. At the end of 48 h of
incubation, C2 ceramide induced a clear time- and dosedependent survival reduction effect on C6 cells. We used
human normal glia cell line (HNA) cells as untransformed
control cells. Treatments with 0.1, 1, and 5 µM ceranib-2
did not change the viability of HNA cells significantly,
but after addition of 10, 25, and 50 µM ceranib-2 to the
culture medium, the percentages of dead HNA cells versus
the control were 20%, 22%, and 28% after 24 h (Table 1),
respectively. Applications of the same six doses of ceranib-2
after 24 h decreased the number of viable T-98G cells by
9% (P > 0.05), 38%, 48%, 53%, 54%, and 61% (P < 0.001);
that of U-87MG cells by 2%, 4%, 11%, 59%, 80%, and 82%;
and that of C6 cells by 7% (P > 0.05), 15%, 27%, 30%, 31%,
and 40% (P < 0.001). Extending the duration of incubation
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of these cells to 48 h further diminished the numbers of
T-98G cells by 10% (P > 0.05), 53%, 60%, 62%, 64%, and
70% (P < 0.001); those of U-87MG by 7%, 10%, 15%, 62%,
83%, and 96%; and those of C6 by 7% (P > 0.05), 15%, 30%,
39%, 40%, and 64% (P < 0.001), respectively. Compared
to cisplatin and C2 ceramide, ceranib-2 showed survival
reduction activity with all six doses used. Ceranib-2 was
also less active on HNA cells than all glioma cells (Table 1).
3.2. Apoptotic results
Used as a positive control, C2 ceramide inhibited the
viability of all three glioma cell lines (Table 1 and 2) but
induced apoptosis only in C6 cells. C2 ceramide at the doses
of 25 and 50 µM added to C6 cells for both durations of time
caused early apoptotic rates of 15% and 36% and of 12%
and 56%, respectively (Table 2). The rates of early apoptotic
T-98G cells were about 18% and 21% after applications of 10
and 25 µM ceranib-2 after 24 h (control: 7%), and 18% and
13% for 48 h (control: 6%; Table 3; Figure 1), respectively.
Exposed to 10 and 25 µM ceranib-2, early apoptotic results
of U-87MG cells were 16% and 37% for 24 h (control:
4%) and 18% and 7% for 48 h (Table 3). According to our
MTT results, since ceranib-2 at higher concentrations was
cytotoxic to C6 cells, we chose only 25 and 50 µM ceranib-2

doses for the apoptosis assay. After applications of 25 and
50 µM ceranib-2, early apoptotic results of C6 were 8%
and 24% (control: 1%) for 24 h and 13% and 52% for 48 h
(against a control value of 3%; Table 3).
3.3. PCR results
The gene expression analysis of the effect of 10 and 25 µM
ceranib-2 was performed only on T-98G cells. Our PCR
results for T-98G cells demonstrated that 10 and 25 µM
ceranib-2 induced a small increase of cytochrome c gene
expression during 24 h of treatment (P > 0.05, Figure 2).
4. Discussion
In the present study, we used two human glioma cell lines
(T-98G and U-87MG), one rat glioma cell line (C6), and
one human normal astrocyte cell line (HNA) to determine
the cytotoxic and apoptotic roles of ceranib-2 compared
to cisplatin and C2 ceramide. Ceranib-2 had the most
growth-suppressive activity on T-98G cells with an IC50
of 7 µM for 24 h and 0.9 µM for 48 h. Calculated from
MTT results, the inhibitory effects of ceranib-2 were in
order of T-98G > U-87MG > C6 > HNA. Interestingly,
HNA cells were less susceptible to ceranib-2. Inhibiting
ceramidase enzyme, the ceramide level may be increased.

Table 2. The influence of C2 ceramide on apoptosis of T-98G, U-87MG, and C6 cells (%) by using annexin V-FITC/PI after 24 or 48 h.
T-98G cells
Viable cells
Early apoptotic cells
Late apoptotic/necrotic cells
U-87MG cells
Viable cells
Early apoptotic cells
Late apoptotic/necrotic cells
C6 cells
Viable cells
Early apoptotic cells
Late apoptotic/necrotic cells
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Time (h)

Control (%)

10 µM C2 ceramide (%)

25 µM C2 ceramide (%)

50 µM C2 ceramide (%)

24

88 ± 3.2

84 ± 4.6

81 ± 3.2

70 ± 3.3

48

86 ± 4.1

76 ± 5

56 ± 4.9

50 ± 5

24

5.5 ± 2.1

6 ± 1.7

3 ± 1.7

4 ± 1.8

48

2 ± 1.6

5 ± 1.6

7 ± 1.4

9 ± 1.5

24

6 ± 2.4

12 ± 2.1

13 ± 2.3

20 ± 2.4

48

10 ± 4.3

13 ± 2.4

17 ± 2.5

18 ± 2.5

Time (h)

Control (%)

10 µM C2 ceramide (%)

25 µM C2 ceramide (%)

50 µM C2 ceramide (%)

24

89 ± 4.3

-

88 ± 3.2

88 ± 3.2

48

82 ± 3.2

-

82 ± 4.2

78 ± 4.1

24

2 ± 1.1

-

2 ± 1.2

2 ± 1.08

48

4 ± 1.9

-

5 ± 1.1

7 ± 2.3

24

5±2

-

5±1

6 ± 1.9

48

9 ± 2.6

-

8 ± 2.2

7 ± 2.3

Time (h)

control (%)

10 µM C2 ceramide (%)

25 µM C2 ceramide (%)

50 µM C2 ceramide (%)

24

90 ± 5

-

58 ± 4.9

27 ± 2.85

48

88 ± 3.6

-

73 ± 2.5

20 ± 2.3

24

4 ± 2.1

-

15 ± 2.14

36 ± 4.45

48

5 ± 2.3

-

12 ± 1.68

56 ± 0.47

24

3±2

-

27 ± 3.8

28 ± 4.8

48

2 ± 4.4

-

13 ± 3.3

21 ± 2.3
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Table 3. The activity of 10, 25, and 50 µM ceranib-2 on apoptosis of T-98G, U-87MG, and C6 cells by using annexin V-FITC/PI after
24 or 48 h.
T-98G cells
Viable cells
Early apoptotic cells
Late apoptotic/necrotic cells
U-87MG cells
Viable cells
Early apoptotic cells
Late apoptotic/necrotic cells
C6 cells
Viable cells
Early apoptotic cells
Late apoptotic/necrotic cells

Time (h)

Control (%)

10 µM ceranib-2 (%)

25 µM ceranib-2 (%)

50 µM ceranib-2 (%)

24

84 ± 5

58 ± 2.4

66 ± 3.1

-

48

86 ± 4.3

36 ± 2.8

61 ± 4.2

-

24

7 ± 2.08

18 ± 2.7

21 ± 2.6

-

48

6 ± 1.6

18 ± 1.6

13 ± 2.4

-

24

9 ± 2.2

12 ± 2.2

9 ± 1.4

-

48

12 ± 2.8

38 ± 2.5

21 ± 2.5

-

Time (h)

Control (%)

10 µM ceranib-2 (%)

25 µM ceranib-2 (%)

50 µM ceranib-2 (%)

24

86 ± 4.8

50 ± 2.1

30 ± 3.4

-

48

83 ± 2.1

50 ± 2.8

10 ± 1.5

-

24

4 ± 1.5

16 ± 1.4

37 ± 2.5

-

48

3 ± 1.8

18 ± 2.6

7 ± 1.2

-

24

6 ± 2.1

26 ± 3.5

33 ± 2.3

-

48

2 ± 0.9

29 ± 2.9

86 ± 3.4

-

Time (h)

Control (%)

10 µM ceranib-2 (%)

25 µM ceranib-2 (%)

50 µM ceranib-2 (%)

24

95 ± 4.9

-

75 ± 3.4

61 ± 3.2

48

87 ± 3.6

-

70 ± 3.2

22 ± 2.8

24

1 ± 0.5

-

8 ± 2.06

24 ± 3.6

48

3 ± 1.5

-

13 ± 2.4

52 ± 4.1

24

3 ± 1.9

-

17 ± 2.5

10 ± 4.3

48

9 ± 2.2

-

11 ± 0.7

15 ± 4

As a result, we detected more cell death with ceranib-2
than even after addition of extra C2 ceramide directly to
the culture medium. Therefore, it is clear that ceranib-2
has a stronger growth inhibitory action than not only
ceramide but also cisplatin. In this regard, it was reported
that ceranib-2 caused reductions in ceramidase activity
and survival of ovarian adenocarcinoma cells (SKOV3)
(Draper et al., 2011). The same study found that ceranib-2
produced a dose-dependent suppression in tumor growth
during in vivo experiments. Similarly, the cytotoxic
activity of ceranib-2 on transformed fibroblast cells
(5RP7) was detected with an IC50 of 3 µM and these effects
were accomplished with indicators of apoptosis such as
fragmented nuclei, chromatin condensations, membrane
shrinkage, dilated Golgi organelles, lipid accumulation,
and extreme mitochondrial degradation (Vejselova et al.,
2014). In addition, ceranib-2 and C2 ceramide caused
reductions in the viability of LNCaP and DU145 prostate
cancer cells (Kus et al., 2015). Interestingly, the same study
found that ceranib-2 had more killing potential than
additional ceramide in these cell lines. It has been recently
indicated in another study that ceranib-2 decreases cell

survival of erythrocytes by triggering cell membrane
scrambling and then causing apoptosis (Signoretto et al.,
2016).
Apoptosis is the one of the most common ways of
physiological cell death in multicellular organisms. Signal
molecules require cooperation with a number of proteins,
including receptors, enzymes, and gene regulatory proteins.
Molecules that induce mitochondrial outer membrane
permeabilization and mitochondrial network breakdown,
both resulting in cytochrome c release, cause apoptosisdependent caspase activation (Gorojod et al., 2017). C2
ceramide did not show any apoptotic effect on T-98G and
U-87MG cells, but it had an apoptotic effect on rat glioma
cells (C6, 56% after 48 h, Table 2). Supporting our results
on C6 cells, according to Sawada (2000), exogenous C2 and
C6 ceramide stimulated apoptosis of C6 cells, which also
augmented the Bax/Bcl-2 and next stimulated caspase-9
and -3 activation followed by cytochrome c release. On
the contrary, Kim et al. (2005) mentioned that ceramide
stimulated cell death, except apoptosis, and this death was
related to accumulation of reactive oxygen species and
lipid peroxidation in a different glioma line (A172). They
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Figure 1. T-98G cells, treated or nontreated with 25 or 50 µM ceranib-2 for 24 (A) or 48 (B) h, then stained with FITC annexin V
apoptosis assay kit with PI (Invitrogen). Lower left sections: annexin V/PI ( − ), living cells; lower right sections: annexin V ( + )/PI ( − ),
early apoptotic cells; upper left sections: annexin ( − )/PI ( + ), necrotic cells; upper right sections: annexin ( + )/PI ( + ), late stages of
apoptosis and secondary necrosis. Results of only one independent experiment out of 3 are depicted.
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morphology and ultrastructure changed significantly,
which indicated apoptotic cell death after exposure to
ceranib-2 (Vejselova et al., 2016). In conclusion, ceranib-2
had stronger cytotoxic and apoptotic effects on some
glioma cells (T-98G, U-87MG, C6) than C2 ceramide and
cisplatin. Moreover, ceranib-2 was less toxic to normal

3

relative expression

also indicated that apoptotic morphological changes could
not be determined by the TUNEL immunohistochemical
method, DNA staining with Hoechst 33258, or flow
cytometric analysis. After comparison to the control, we
found that 10 and 25 µM ceranib-2 increased the early
apoptotic rate in T-98G and U-87MG cells. This effect was
stronger on U-87MG cells. Ceranib-2 at the doses of 25 and
50 µM also induced a dose-dependent early apoptosis of
C6 cells, at 52% for 48 h (Table 1). PCR data of the current
study indicated that cytochrome c mRNA expression level
was slightly raised by both 10 and 25 µM concentrations
for T-98G during 24 h, but this change was not significant.
The increasing of apoptosis of glioma cells, and especially
T-98G cells, after treatment with ceranib-2 may be due
to the cytochrome c level rising. Similar to our ceranib-2
results, cytotoxic effects, apoptotic properties (fragmented
nuclei, condensed chromatin, late apoptotic bodies,
cell shrinkage), and an increased number of annexin
V-positive cells were observed in ceranib-2-treated MCF7
and MDA MB 231 cell lines (Vethakanraj et al., 2015).
Similarly, it was recently indicated in another study that
after 24 h of incubation ceranib-2 clearly diminished the
number of MCF7 cells, causing apoptosis by diminishing
the mitochondrial membrane potential. In addition, cell

2

1

0
control

10

25

Figure 2. Relative gene expression changes in cytochrome c
enzyme level after application of 10 and 25 µM doses of ceranib-2
to T-98G cells after 24 h (P > 0.05).
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human astrocyte cells (NHAs). Our results may promote
new insights for glioma treatment with ceranib-2.
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